Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bitwise Crypto Industry Innovators ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Bitwise Crypto Industry Innovators ETF trades at $25.27. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | BITQ | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Crypto-linked |
52-Week High | $28.06 | $30.43 |
52-Week Low | $20.06 | $16.74 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BITQ trades at $24.83, up 4.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is firm near $24, while resistance sits at $25-$26. The ETF's performance remains tied to crypto industry sentiment, with recent news highlighting investor outflows from Bitcoin ETFs amid market volatility. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to bearish technicals and sector headwinds. Opportunities exist if crypto markets rebound, but risks include regulatory uncertainty and reliance on volatile underlying assets. Investors should monitor ETF inflows and broader crypto adoption trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
